Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

Quach, Hang

Oral and Poster Abstracts
653. Multiple Myeloma: Prospective Therapeutic Trials: Poster I

Research, clinical trials, Combination therapy, Clinical Research, Therapies, Adverse Events

Hang Quach, MD, FRACP, FRCPA, MBBS^1,2, Masa Lasica^2,3^*, Michael Low⁴^*, Peter Mollee, FRACP, MBBS, MSc, FRCPA^5,6, Hock Choong Lai, MBBS, FRACP, FRCPA⁷^*, Nicole Wong Doo, MBBS, MD, FRACP, FRCPA^8,9, Jay Hocking, MBBS, FRACP, FRCPA, PhD¹⁰^*, Philip Campbell, MBBS¹¹, Nicholas E. Murphy, MBBS, FRACP, FRCPA¹²^*, M Hasib Sidiqi, MBBS, FRACP, FRCPA^13,14^*, David Routledge, BSc, MBChB, MSc, PGCert, MRCP UK, FRCPath UK, FRACP^15,16,17, Jessica Heenan, MBBS, FRACP, FRCPA¹⁸^*, Noemi Horvath, MBBS, FRACP, FRCPA¹⁹, Richard Eek, MBChB, MMed²⁰^*, William E. P. Renwick, MBBS^2,21, Douglas Stuart Lenton, MBBS, FRACP, FRCPA²²^*, Lauren J Child, MBChB, RACP, RCPA²³^*, Georgia McCaughan, BMedSc MBBS MMed (Clin Epi) FRACP FRCPA²⁴^*, Belinda E Butcher, PhD^25,26^*, Deepmala Mazumdar, PhD²⁷^* and Anna Kalff, MBBS, FRACP, FRCPA^28,29

¹Department of Haematology, St Vincent’s Hospital Melbourne, Victoria, Australia, Melbourne, VIC, Australia
²Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia, Melbourne, VIC, Australia
³Department of Haematology, St Vincent’s Hospital Melbourne, Victoria, Australia, Fitzroy, VIC, Australia
⁴Monash Haematology, Monash University, Clayton University, Victoria, Australia
⁵Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
⁶Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia
⁷Townsville Cancer Centre, Townsville Hospital, Queensland, Australia, Townsville, QLD, Australia
⁸Department of Haematology, Concord Hospital, University of Sydney, New South Wales, Australia, Concord, NSW, AUS
⁹Concord Clinical School, Faculty of Medicine and Health, University of Sydney, Australia, Concord, NSW, Australia
¹⁰Department of Clinical Haematology, Austin Health, Victoria, Australia, Melbourne, VIC, Australia
¹¹Department of Haematology, University Hospital Geelong, Barwon Health, Victoria, Australia, Geelong, VIC, AUS
¹²Department of Haematology, Royal Hobart Hospital, Tasmania, Australia, Hobart, TAS, AUS
¹³Department of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia, Murdoch, Western Australia, AUS
¹⁴Curtin Medical School, Curtin University, Western Australia, Bentley, Western Australia, Australia
¹⁵Department of Clinical Haematology, Peter MacCallum Cancer Centre, Victoria, Australia, Melbourne, VIC, Australia
¹⁶Department of Clinical Haematology, The Royal Melbourne Hospital, Victoria, Australia, Melbourne, VIC, Australia
¹⁷Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia, Melbourne, VIC, Australia
¹⁸Department of Haematology, Holman Clinic, Launceston General Hospital, Tasmania, Australia, Launceston, TAS, Australia
¹⁹Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital, South Australia, Adelaide, Sa, AUS
²⁰Department of Haematology, Border Medical Oncology, New South Wales, Australia, Wodonga, AUS
²¹Haematology Oncology, Western Health, Victoria, Australia, Melbourne, AUS
²²Department of Haematology, Orange Hospital, New South Wales, Australia, Orange, NSW, AUS
²³Auckland Regional Blood and Cancer Service, Auckland City Hospital, Auckland, New Zealand, Auckland, New Zealand
²⁴Haematology Department, The Kinghorn Cancer Centre, St Vincent's Hospital, Darlinghurst, NSW, Australia
²⁵School of Biomedical Sciences, UNSW, UNSW Sydney, NSW, Australia, Sydney, NSW, Australia
²⁶WriteSource Medical Pty Ltd, Lane Cove, NSW, Australia, Lane Cove, Australia
²⁷Australasian Leukaemia & Lymphoma Group, Victoria, Australia, Melbourne, VIC, Australia
²⁸Department of Clinical Haematology, Monash Medical Centre, Clayton, Victoria, Australia, Melbourne, VIC, Australia
²⁹Malignant Haematology and Stem Cell Transplantation Services, Alfred Hospital, Melbourne, Victoria, Australia, Prahran, VIC, AUS

Introduction:

Upregulation of Exportin 1(XPO1), a molecule that mediates nuclear export of tumor suppressor proteins, is associated with poor prognosis and resistance to immunomodulatory drugs (IMiD) and proteasome inhibitors in myeloma (MM). Selinexor (S) is an oral selective XPO1 inhibitor, that is approved in combination with bortezomib and dexamethasone to treat adult patients with MM who have received at least one prior therapy. We hypothesize that low dose S when combined with low dose lenalidomide (R) will be synergistic and will improve progression free survival (PFS) compared to R maintenance post autologous stem cell transplant (ASCT) in patients (pts) with transplant eligible (TE) newly diagnosed (NDMM). We report here the results of the planned futility analysis, after at least 30 patients had completed a minimum of 6 months follow-up in the phase III randomized SeaLAND (ALLG MM23) study (ANZCTR12620000291987).

Method:

Eligible pts were TE NDMM who have had 3 to 6 cycles of induction containing bortezomib (V), dexamethasone ± R. Registration occurred pre-ASCT; screening and randomization occurred from day 75 to 115 post-ASCT. Twenty pts in the lead in safety phase were given low-dose S [40mg (increased to 60mg from C2 if well tolerated) po D1,8,15,22] with R (15mg D1 to 21; 10mg in C1 to 3) in a 28-day cycle. Upon review by the independent safety committee in May 2023, after the first twenty pts had completed 2 cycles of SR, a starting dose of S of 40mg/week was deemed generally safe with no escalation recommended. Subsequent patients were randomized 1:1 to either SR (S capped at 40mg/week) or R. Primary objective was to determine 3-year-PFS; secondary objectives included safety/tolerability and additional efficacy measurements.

Results:

As of 30 May 2023, 117 pts (70% male) received maintenance (69 pts SR; 48pts R). 103 patients (61 SR and 42 R) had clean data at a cut-off date and were included in this analysis. Median (med) age was 60 (range 34-75). 27.4% of patients had high risk cytogenetics; ISS stage 1,2,3 occurred in 31.5%, 47% and 26.5%, respectively. Med follow-up for the overall group was 11.9 (0.3-28) months, with a med 10 (1-27) cycles [10 (1-27) SR; 9.5 (2-21) R] and 86.1% of patients continued treatment (83.1% SR; 90.7% R). All patients (n=103) had ≥ 1 treatment-emergent adverse event (TEAE); 64% grade (Gr) 3-4 (84% SR, 36% R); SAE occurred in 21% (28% SR, 12% R). Hematologic Gr 3-4 TEAEs were anemia (1.6% SR; 4.8% R), neutropenia (60.7 SR; 28.6% R) and thrombocytopenia (24.6% SR; 0% R). Gastrointestinal TEAE occurred in 50.4% of all patients (67.5% SR, 26.2% R). Diarrhea, nausea and vomiting in the SR (Gd 3-4)/R (Gd 3-4) group occurred in 26.3% (3.3%)/23.8% (2.4%), 57.1% (9.8%)/7.1% (0%), and 8.2% (1.6%)/0% (0%), respectively. The incidence of gastrointestinal TEAE in the SR group decreased from C3 onwards. Infections occurred in 41% of all patients (49% SR, 29% R); Gd 3-4 infections in 9 % (15% SR, 0% R). COVID-19 infections occurred in 16% (13% SR; 19% R), and all but one was Gd 1-2. 1 patient died (SR arm) due to progressive disease. In the SR group, the med RDI (relative dose intensity) of S was 66.7% (20.8-150%), and in the R group; the med RDI of R was 100% (33.3-100%). Most patients in the SR arm (n=61) tolerated S dose between 80mg (20mg per week) to 160mg (40mg per week), which remained consistent with time (figure 1).

Conclusion:

A dose of S 40mg weekly was generally tolerable when combined with R 10-15mg days 1-21 in a 28-day cycle, as maintenance therapy post ASCT. The safety profile was consistent with each of S and R individually. Recruitment in the ALLG MM23 (SeaLAND) study is ongoing and updated safety and treatment data will be presented at the meeting.

Acknowledgement: Patients, their families, and participating ALLG members and member sites. ALLG acknowledges the support of Karyopharm for funding and Selinexor supply.

Disclosures: Quach: Abbvie: Consultancy; Karyopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: receipt of study materials, Research Funding; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: receipt of study materials; Leadership or fiduciary role, Research Funding; Antengene: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Research Funding; Janssen: Consultancy; Sanofi: Consultancy, Honoraria, Other: receipt of study materials, Research Funding; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Leadership or fiduciary role, Research Funding. Lasica: JanssenJanssen: Other: Education; Celgene: Other: TRAVEL, ACCOMMODATIONS, EXPENSES. Mollee: Cilag: Research Funding; Pfizer: Research Funding; Janssen: Research Funding. Sidiqi: Pfizer: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Antengene: Speakers Bureau; Gilead: Speakers Bureau; BMS: Speakers Bureau. Renwick: Astra Zeneca: Research Funding. McCaughan: BMS: Honoraria; Janssen: Honoraria.

OffLabel Disclosure: Selinexor used as maintenance therapy for Myeloma post autologous stem cell transplant.

See more of: 653. Multiple Myeloma: Prospective Therapeutic Trials: Poster I
See more of: Oral and Poster Abstracts

<< Previous Abstract | Next Abstract >>

^*signifies non-member of ASH

2023 Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)